FTRP FIELD TRIP HEALTH LTD

Field Trip Health Ltd. to Participate in Upcoming Conferences in November 2021

Field Trip Health Ltd. to Participate in Upcoming Conferences in November 2021

TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that during the month of November management will attend the Microdose Wonderland: Miami Conference and present at the Stifel 2021 Virtual Healthcare Conference and the Jefferies London Healthcare Conference.

Wonderland: Miami Conference

Field Trip’s Co-founder and Executive Chairman, Ronan Levy will attend the Microdose Wonderland: Miami conference taking place between November 8-9, 2021 to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL.

Stifel 2021 Virtual Healthcare Conference

Field Trip’s Co-founder and Executive Chairman, Ronan Levy, and Field Trip’s Chief Scientific Officer, Dr. Nathan Bryson, will present live at the Stifel Virtual Healthcare Conference at 8:00am ET on Wednesday, November 17, 2021. The presentation will be webcast and available through this link: .

Jefferies London Healthcare Conference

Field Trip’s management team will present virtually at the Jefferies London Healthcare Conference, taking place on November 18-19. The webcast will be available to registered attendees on-demand, beginning on Thursday, November 18, 2021 at 3:00am ET through Friday, November 19, 2021 at 12:00pm ET. To view the webcast, please visit this link: .

Field Trip’s management team will be available for one-on-one meetings throughout the duration of the conferences. To schedule a meeting with Field Trip’s management team, please contact KCSA Strategic Communications at .

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at , and .

Follow us on Twitter and Instagram: @fieldtriphealth.

To receive company updates about Field Trip and to be added to the email distribution list please sign up .

Cautionary Note Regarding Forward-Looking Information 

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at and on the EDGAR section of the SEC’s website at

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Media contacts:

Rachel Moskowitz

Autumn Communications

202-276-7881

Nick Opich / McKenna Miller

KCSA Strategic Communications

212-896-1206 / 347-487-6197

Investor contacts:

Kathleen Heaney / Tim Regan

KCSA Strategic Communications

SOURCE Field Trip Health Ltd.



EN
03/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIELD TRIP HEALTH LTD

 PRESS RELEASE

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxi...

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA. The ...

 PRESS RELEASE

Reunion Neuroscience Inc. to Participate in October Investor Conferenc...

Reunion Neuroscience Inc. to Participate in October Investor Conferences WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to schedule a 1x1 meeting with the company. Event:Oppenheimer Private Company ShowcaseFormat:Presentation by Greg Mayes, pr...

 PRESS RELEASE

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application t...

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression WILMINGTON, Del., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the...

 PRESS RELEASE

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Pla...

Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately...

 PRESS RELEASE

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan ...

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to announce that, earlier today, the Ontario Superior Court of Justice (Commercial List) granted a final order approving the proposed arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch